magnesium trisilicate
Approved
Dec 9, 1983
Talcum powder is made from talc, a mineral made up mainly of the elements magnesium, silicon, and oxygen. As a powder, it absorbs moisture well and helps cut down on friction, making it useful for keeping skin dry and helping to prevent rashes. It is widely used in cosmetic products such as baby powder and adult body and facial powders, as well as in a number of other consumer products. The therapeutic action of talc instilled into the pleural cavity is believed to result from induction of an inflammatory reaction. This reaction promotes adherence of the visceral and parietal pleura, obliterating the pleural space and preventing reaccumulation of pleural fluid. Sterile Talc Powder, administered intrapleurally via chest tube, is indicated as a sclerosing agent to decrease the recurrence of malignant pleural effusions in symptomatic patients. The most often reported adverse experiences to intrapleurally-administered talc were fever and pain. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 5 marketing orgs
Earliest trial started Jul 31, 2016 (NCT03516188)
Timeline
1980s
- Dec 9, 1983
Sanofi — Earliest FDA Approval
- Dec 9, 1983
Sanofi-Aventis — NDA Secondary Org
- Dec 9, 1983
Sanofi — NDA Secondary Org
- Dec 9, 1983
Sanofi — NDA Organization
- Sep 4, 1987
Guardian Drug — Marketing Organization
- Jun 28, 1989
Novartis — Marketing Organization
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Neutralises acid
- Unspecified targetBuffer
buffer
Combination products
gaviscon
with aluminum hydroxide
Also known as foamcoat, foamicon
Approval history
- approvedDec 9, 1983
Chemistry & pharmacology
SMILES
[O--].[O--].[O--].[Mg++].[Si+4]- Mol. weight
- 100.3887 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaMagnesium trisilicate ↗
- NCATS9B9691B2N9 ↗
- ChEMBLCHEMBL2109133 ↗
- ChEMBLCHEMBL2096633 ↗
Also known as
- magnesium mesotrisilicate
- magnesium silicate
- magnesium silicate
- magnesium silicate
- magnesium silicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate
- magnesium trisilicate hexahydrate (mg4(h2si6o17))
- magnesium trisilicate hexahydrate ((mg9h14(si3o10)4))
- magnesium trisilicate hydrate
- magnesium trisilicate (mg2(h4si3o10))
- magnesium trisilicate tetrahydrate (mg4(h6si6o19))
- mag trisil co
- sepiolite
- trimax
- trimax
- trisilicalm
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06040190 | Phase 4 | Nov 1, 2023 | Federal University of Minas Gerais |
| NCT03516188 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2016 | University of Science Malaysia |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Federal University of Minas Gerais | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Science Malaysia | Academic/Hospital | 1 | 1 | 1 | 2016 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Guardian Drug | For profit | MKTG | Sep 4, 1987 |
| Novartis | For profit | MKTG | Jun 28, 1989 |
| PENNEX | For profit | MKTG | — |
| Sanofi | For profit | NDA2 | Dec 9, 1983 |
| Sanofi | For profit | NDA | Dec 9, 1983 |
| Sanofi-Aventis | For profit | NDA2 | Dec 9, 1983 |